In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Enliven Therapeutics Inc’s stock clocked out at $17.28, down -2.21% from its previous closing price of $17.67. In other words, the price has decreased by -$2.21 from its previous closing price. On the day, 0.76 million shares were traded. ELVN stock price reached its highest trading level at $18.51 during the session, while it also had its lowest trading level at $15.96.
Ratios:
To gain a deeper understanding of ELVN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.28 and its Current Ratio is at 10.28. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 09, 2024, initiated with a Buy rating and assigned the stock a target price of $34.
On March 29, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $27.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 15 ’24 when Heyman Richard A. sold 1,270 shares for $19.99 per share. The transaction valued at 25,383 led to the insider holds 137,155 shares of the business.
Ballal Rahul D. sold 53,400 shares of ELVN for $1,279,068 on Apr 11 ’24. The Director now owns 22,341 shares after completing the transaction at $23.95 per share. On Apr 11 ’24, another insider, Kintz Samuel, who serves as the PRESIDENT AND CEO of the company, sold 47,709 shares for $25.04 each. As a result, the insider received 1,194,700 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 808797376 and an Enterprise Value of 461674080.
Stock Price History:
Over the past 52 weeks, ELVN has reached a high of $26.00, while it has fallen to a 52-week low of $9.80. The 50-Day Moving Average of the stock is 1.96%, while the 200-Day Moving Average is calculated to be 14.49%.
Shares Statistics:
It appears that ELVN traded 243.02K shares on average per day over the past three months and 731570 shares per day over the past ten days. A total of 41.29M shares are outstanding, with a floating share count of 25.32M. Insiders hold about 45.90% of the company’s shares, while institutions hold 45.49% stake in the company. Shares short for ELVN as of 1711584000 were 4232833 with a Short Ratio of 17.42, compared to 1709164800 on 4334002. Therefore, it implies a Short% of Shares Outstanding of 4232833 and a Short% of Float of 14.760000000000002.
Earnings Estimates
A detailed examination of Enliven Therapeutics Inc (ELVN) is currently in progress, with Elevance Health, Inc. analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $50.05, with high estimates of $3.12 and low estimates of $12.95.
